$BCAX News
Last published 2d ago
- 2d agoBCAXBicara Therapeutics Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoBCAXBicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAchieved substantial enrollment in FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC; topline results from interim analysis expected in mid-2027
- 2d agoBCAXBicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAchieved substantial enrollment in FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC; topline results from interim analysis expected in mid-2027 Enrolling FORTIFI-FLEX alternate dosing study; expect to have data
- 2d agoBCAXBicara Therapeutics Q3 2026 Earnings Call - BICARA THERAPEUTICS INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Bipara Therapeutics 3rd Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will
- 1w agoBCAXBicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 1w agoBCAXBicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ETGlobeNewswireBOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 2mo agoBCAXBicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 2mo agoBCAXBicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 3mo agoBCAXBicara Therapeutics Q2 2026 Earnings Call - BICARA THERAPEUTICS INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Bacara Therapeutics Second Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'l
- 3mo agoBCAXBicara Therapeutics Q2 2026 Earnings Call - BICARA THERAPEUTICS INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Bacara Therapeutics Second Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'l
- 3mo agoBCAXBicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and GrowthGlobeNewswirePresident & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board of
- 3mo agoBCAXBicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ETGlobeNewswireBOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 3mo agoBCAXBicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of DirectorsGlobeNewswireBOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 4mo agoBCAXBicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 5mo agoBCAXFicerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCCGlobeNewswireAt a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis
- 6mo agoBCAXBicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 6mo agoBCAXBicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireStudy to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up data from Phase
- 6mo agoBCAXBicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ETGlobeNewswireBOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 7mo agoBCAXBicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 7mo agoBCAXBicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireSelected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading and
- 7mo agoBCAXBicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ETGlobeNewswireBOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 8mo agoBCAXBicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 8mo agoBCAXBicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireBOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 8mo agoBCAXBicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireBOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 8mo agoBCAXBicara Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswireBOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 8mo agoBCAXBicara Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 8mo agoBCAXFicerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing RegimenGlobeNewswirePhase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients demonstrate rapid, deep and durable responses with generally
- 9mo agoBCAXBicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 10mo agoBCAXBicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate OutlookGlobeNewswireSelected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study Expects to achieve substantial enrollment in FORTIFI-HN01 in 2026 to enable
- 11mo agoBCAXBicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12GlobeNewswireBOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 11mo agoBCAXBicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026GlobeNewswireFicerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study interim analysis
- 11mo agoBCAXBicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025GlobeNewswireFicerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW dose Data inform and advance progress toward dose selection for ongoing
- 11mo agoBCAXIOBTNVSOTLC+1Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting ForGlobeNewswireAUSTIN, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As late-stage biotech pipelines mature, fair-value remeasurements under U.S. Generally Accepted Accounting Principles (GAAP) are emerging
- 1y agoBCAXBicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireGranted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly in
- 1y agoIOBTNVSBCAXPFENanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in OncologyPR NewswireThe global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce toxicity and improve patient...
- 1y agoBCAXBicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCCGlobeNewswireBOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 1y agoBCAXBicara Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 1y agoBCAXBicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireUpdated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating alternate dose
- 1y agoBCAXBCYCBOLDRice Biotech Launch Pad welcomes Carolyn Ng to external advisory boardPR NewswireThe Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology...
- 1y agoBBNXBCAXKMTSMORF+2Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science CompaniesBusiness WireOmega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The
- 1y agoBCAXRLAYRelay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational
- 1y agoBCAXBicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewswireBOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 1y agoBCAXBicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025GlobeNewswireMedian DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC
- 1y agoBCAXBicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual MeetingGlobeNewswireBOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 1y agoBCAXBicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireUpdated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Enrollment ongoing in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC
- 1y agoBCAXBicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025GlobeNewswireBOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 1y agoBCAXBicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireBOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 1y agoBCAXBicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswireDosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting
- 1y agoBCAXBicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025GlobeNewswireBOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,
- 1y agoBCAXBicara Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswireBOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors,